Dopamine/Serotonin Receptor Ligands. Part IV [1]: Synthesis and Pharmacology of Novel 3-Benzazecines and 3-Benzazonines as Potential 5-HT2A and Dopamine Receptor Ligands
LE 300 represents a structurally novel type of antagonist acting preferentially at the dopamine D1/D5 receptors and the serotonin 5‐HT2A receptor. The compound consists of a 10‐membered central azecine ring fused to indole on one and to benzene on the other side.To estimate the importance of the indole moiety in this highly active benz‐indolo‐azepine, the indole has to be removed and the “de‐indolised”